GLP1R and type 2 diabetes mellitus: The GLP-1 analog exenatide significantly improved endothelial function in coronary circulation of patients with type 2 diabetes and increased NO production through activation of the phosphatidylinositol-3 kinase (PI3K)/Akt/AMPK/eNOS pathway via a GLP-1 receptor-dependent mechanism in a dose-dependent manner in HUVEC [121].